Core Viewpoint - The company, Jin Yong Investment (01328.HK), has signed a strategic cooperation framework agreement with Guofu Quantum Innovation Co., Ltd. to explore potential collaborations in the capital markets, particularly in RWA tokenization and digital asset management [1] Group 1: Strategic Cooperation - The strategic cooperation aims to leverage the deep relationship between Jin Yong Investment and Hongyi Investment Group, as well as the potential synergies with Guofu Quantum [1] - The agreement includes exploring opportunities in RWA tokenization product design and issuance, quality RWA project investment allocation, and digital asset trading and asset management services [1] - The company believes that this strategic cooperation agreement is a strong testament to its business capabilities and potential [1] Group 2: Business Diversification - The board of directors views the proposed cooperation under the strategic cooperation agreement as an opportunity for the company to diversify its revenue sources [1] - The signing of the strategic cooperation agreement aligns with the overall interests of the company and its shareholders [1]

香港交易及結算所有限公司以及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 GOLDSTREAM INVESTMENT LIMITED 金涌投資有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1328） 自願公告 與國富量子創新有限公司之戰略合作 本公告乃由金涌投資有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願作出， 以通知本公司股東及潛在投資者有關本公司最近期之業務發展。 戰略合作協議 董事會欣然宣佈，有鑑於（其中包括）本集團與弘毅投資集團間的深厚關係，以及與國富 量子創新有限公司（「國富量子」），一家於開曼群島註冊成立之有限公司，其已發行股份 於聯交所主板上市（股份代號：290）（「國富量子」）之間的潛在戰略協同效應，本公司與 國富量子於2025年8月26日簽訂戰略合作框架協議備忘錄（「戰略合作備忘錄」）。 根據戰略合作協議，本公司與國富量子擬探索資本市場領域開展友好合作的可能性，包 括但不限於RWA代幣化產品設計及發行、優質RWA項目投資配置，數字資產交 ...

Core Viewpoint - The collaboration between Chengdu Berry Genomics Co., Ltd. and its partners aims to drive innovation in medical technology and industry upgrades through digital assetization, exploring RWA applications to reshape the global gene diagnostic asset value chain and maximize asset value [1][2]. Group 1: Company Overview - Berry Genomics focuses on technological innovation to advance precision medicine, utilizing high-throughput sequencing technology to create solutions across various fields, including reproductive health and genetic disease testing [2]. - The company has pioneered the clinical transformation of third-generation HiFi sequencing technology and has successfully launched multiple products, establishing a strong technological moat [2]. Group 2: Collaboration Details - The partners plan to use the stable revenue from Berry Genomics' third-generation HiFi sequencing production line and the technical service income from the GENOisi™ intelligent system as underlying assets for digital rights exploration and RWA tokenization [4]. - The project aims to quantify the value of the GENOisi™ intelligent system as a new type of digital asset, accelerating the integration of technology and capital, thereby injecting new momentum into the sustainable development of precision medicine [4]. Group 3: Future Directions - This collaboration represents a critical step in the digitalization of healthcare assets, standardizing data rights in the medical health sector and enhancing the quantification and circulation of new digital assets like AI intelligent systems [5]. - The company intends to deepen technical and resource collaboration with partners, actively exploring more digital paths for medical assets, contributing to the popularization of precision medicine, data value extraction, and the upgrade of the global healthcare ecosystem [5].

8月15日，国富量子(00290)开盘即录得超6%涨幅。消息面上，公司于8月14日晚间披露重磅融资计划， 宣布与11名认购人签订协议，将配发及发行合计约9.15亿股新股份，每股认购价定为1.45港元，预计募 资总额约13.26亿港元。据测算，此次发行的新股份占公司现有已发行股本比例约10.05%，扣除相关费 用后，募集资金净额约13.21亿港元，将按比例投向四大核心领域。 构建全生命周期生态打造多维竞争壁垒 募资用途明确四大方向聚焦RWA生态 根据公告披露，本次募集资金净额约13.21亿港元，将重点投向以下四个方向： 20%用于拓展数字资产金融牌照业务与基础设施; 10%用于拓展RWA投行业务; 45%用于发展pre-RWA及RWA二级市场基金; 25%用于投资金融科技及开发RWA技术平台及探索应用场景，包括与京北方（002987）成立合资公司及 相关技术研发与应用场景拓展。 国富量子在公告中强调，此次募资旨在加码布局RWA(实物资产代币化)赛道，构建"交易所—RWA投行 —pre-RWA基金—RWA二级市场基金—金融科技"的全生命周期生态闭环，形成"合规入口—资产获取— 资产增值—技术底座"的多维竞争优势， ...

根据公告披露，本次募集资金净额约13.21亿港元，将重点投向以下四个方向： 20% 用于拓展数字资产金融牌照业务与基础设施; 智通财经APP获悉，8月15日，国富量子(00290)开盘即录得超6% 涨幅。消息面上，公司于 8 月 14 日晚 间披露重磅融资计划，宣布与 11 名认购人签订协议，将配发及发行合计约 9.15 亿股新股份，每股认购 价定为 1.45 港元，预计募资总额约 13.26 亿港元。据测算，此次发行的新股份占公司现有已发行股本比 例约 10.05%，扣除相关费用后，募集资金净额约 13.21 亿港元，将按比例投向四大核心领域。 募资用途明确 四大方向聚焦 RWA 生态 10% 用于拓展RWA投行业务; 构建全生命周期生态 打造多维竞争壁垒 4.RWA 二级市场基金：通过设立二级市场投资基金、做市基金及抵押信贷基金优化资产流动性，专注 已上链资产的投融资、流动性支持与退出管理，提升市场效率与周转率。 5.金融科技：作为 RWA 业务的技术底座，公司已与金融科技领军企业京北方(2987.SZ)成立合资公司， 整合其在金融 IT、智能风控等领域的技术资源;同时聚焦 RWA 核心技术平台研发，涵盖 ...

Group 1 - The company, Guofu Quantum, has signed subscription agreements with 11 subscribers to issue a total of 915 million subscription shares at a price of HKD 1.45 per share, representing approximately 9.13% of the enlarged share capital [2] - The total amount raised from this placement is approximately HKD 13.264 billion, with a net amount of about HKD 13.214 billion [2] - The proceeds will be allocated as follows: 20% for expanding digital asset financial license business and infrastructure, 10% for expanding RWA investment banking business, 45% for developing Pre-RWA funds and RWA secondary market funds, and 25% for investing in fintech and RWA technology platforms [2]

Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]

格隆汇8月14日丨国富量子(00290.HK)公告，于2025年8月14日，公司与十一(11)名认购人订立十一(11) 份独立认购协议，据此，公司有条件同意向认购人配发及发行，而认购人有条件同意认购合共 914,758,614股认购股份，认购价为每股认购股份1.45港元。 认购价每股认购股份1.45港元较股份于2025年8月14日(即认购协议日期)在联交所所报收市价每股1.65港 元折让约12.12%；透过认购事项筹集所得款项总额及所得款项净额(经扣除认购事项相关成本及开支后) 将分别约为13.26亿港元及13.2亿港元。按此基准，认购股份认购净价将为每股认购股份约1.44港元。 ...

Group 1 - The company, Guofu Quantum (00290), announced a conditional agreement with 11 subscribers to issue a total of 915 million subscription shares, representing approximately 9.13% of the enlarged issued share capital after the issuance [1] - The subscription price is set at HKD 1.45 per share, which is a discount of about 12.12% compared to the closing price of HKD 1.65 on August 14 [1] - The total amount raised from the subscription is approximately HKD 13.264 billion, with a net amount of about HKD 13.214 billion [1] Group 2 - The net proceeds will be allocated as follows: 20% for expanding digital asset financial license business and infrastructure, 10% for expanding RWA investment banking business, 45% for developing Pre-RWA funds and RWA secondary market funds, and 25% for investing in fintech and RWA technology platforms, including a joint venture with Jingbeifang (002987) [1]

Group 1 - The company, Guofu Quantum (00290), announced a conditional agreement with 11 subscribers to issue a total of 915 million subscription shares, representing approximately 9.13% of the enlarged issued share capital after the issuance [1] - The subscription price is set at HKD 1.45 per share, which is a discount of about 12.12% compared to the closing price of HKD 1.65 on August 14 [1] - The total gross proceeds from the subscription are expected to be approximately HKD 13.264 billion, with net proceeds of about HKD 13.214 billion [1] Group 2 - The net proceeds will be allocated as follows: 20% for expanding digital asset financial license business and infrastructure, 10% for expanding RWA investment banking business, 45% for developing Pre-RWA funds and RWA secondary market funds, and 25% for investing in fintech and RWA technology platforms, including establishing a joint venture with Jingbeifang and related technology research and application [1]